YB:NASDAQYuanbao Inc. Analysis
Data as of 2026-05-12 - not real-time
Latest Price
Risk Level: Medium
Executive Summary
Yuanbao Inc. trades at $15.81, well below its 20‑day ($16.73), 50‑day ($17.95) and 200‑day ($21.04) moving averages, signaling a bearish technical backdrop. The RSI of 39.9 and a bearish MACD histogram reinforce short‑term downside pressure, while the price sits just above a solid support at $15.06 with resistance near $18.80. Despite the technical weakness, the fundamentals are exceptionally strong: revenue grew 32% YoY, gross margins sit at 96%, operating margins at 34%, and ROE exceeds 50%. Valuation metrics are strikingly cheap, with a trailing PE of 3.9 versus an industry average of 39, a price‑to‑sales of 0.17 and a forward PE of 3.2, suggesting a potential upside of roughly 40% to the consensus target of $22.07. The company holds $3.96 bn in cash against minimal debt, and its beta of 1.16 and 30‑day volatility of nearly 50% indicate heightened market sensitivity. The Fear & Greed Index reading of “Extreme Greed” reflects strong market appetite, yet the low trading volume and modest market cap raise liquidity concerns. Overall, YB presents a classic value‑growth dichotomy: compelling fundamentals and valuation upside countered by bearish technicals and elevated risk factors.
Market Outlook
Short Term
< 1 yearKey Factors
- Price below key moving averages indicating bearish momentum
- Proximity to support level at $15.06
- High short‑term volatility and low trading volume
Medium Term
1–3 yearsKey Factors
- Robust revenue growth of 32% and high profitability margins
- Significant valuation discount (PE 3.9 vs industry 39)
- Strong cash position relative to minimal debt
Long Term
> 3 yearsKey Factors
- Sustained high ROE and ROA indicating efficient capital use
- Potential upside to analyst target price of $22.07 (+~40%)
- Long‑run market share expansion in China’s insurance brokerage sector
Key Metrics & Analysis
Financial Health
Technical Analysis
Valuation
Risk Assessment
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.